Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (1): 52-57.DOI: 10.3969/j.issn.1673-8640.2026.01.009
Previous Articles Next Articles
ZHOU Chaoqiong1, CHEN Ting2, KONG Lirui3, MA Chunyu4(
)
Received:2024-06-30
Revised:2025-04-11
Online:2026-01-30
Published:2026-01-30
Contact:
MA Chunyu
CLC Number:
ZHOU Chaoqiong, CHEN Ting, KONG Lirui, MA Chunyu. Clinical role of gene mutation types and MCV,MCH levels in patients with thalassemia in Pidu District of Chengdu City[J]. Laboratory Medicine, 2026, 41(1): 52-57.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.01.009
| 基因型 | 例数/例 | 检出率/% |
|---|---|---|
| 静止型 | ||
| -α3.7/αα | 51 | 24.52 |
| αCS/αα | 9 | 4.33 |
| -α4.2 / αα | 8 | 3.85 |
| αQS/αα | 2 | 0.96 |
| 轻型 | ||
| --SEA/ αα | 130 | 62.50 |
| 中间型 | ||
| --SEA/-α3.7 | 5 | 2.40 |
| 罕见型 | ||
| HBA1:IVS-Ⅰ-49 | 1 | 0.48 |
| HBA1:c.-35T>C | 1 | 0.48 |
| HBA2:IVS-Ⅱ-55 HBA2:IVS-Ⅱ-119 | 1 | 0.48 |
| 基因型 | 例数/例 | 检出率/% |
|---|---|---|
| 静止型 | ||
| -α3.7/αα | 51 | 24.52 |
| αCS/αα | 9 | 4.33 |
| -α4.2 / αα | 8 | 3.85 |
| αQS/αα | 2 | 0.96 |
| 轻型 | ||
| --SEA/ αα | 130 | 62.50 |
| 中间型 | ||
| --SEA/-α3.7 | 5 | 2.40 |
| 罕见型 | ||
| HBA1:IVS-Ⅰ-49 | 1 | 0.48 |
| HBA1:c.-35T>C | 1 | 0.48 |
| HBA2:IVS-Ⅱ-55 HBA2:IVS-Ⅱ-119 | 1 | 0.48 |
| 基因型 | 例数/例 | 检出率/% |
|---|---|---|
| 轻型 | ||
| CD17 | 88 | 39.12 |
| IVS-Ⅱ-654 | 55 | 24.45 |
| CD41-42 | 48 | 21.33 |
| CD43 | 8 | 3.56 |
| CD27-28 | 6 | 2.67 |
| βE | 6 | 2.67 |
| -28 | 5 | 2.22 |
| CD71-72 | 4 | 1.78 |
| 罕见型 | ||
| CD37 | 1 | 0.44 |
| -31 | 1 | 0.44 |
| CD59 | 1 | 0.44 |
| IVS-Ⅱ-143 | 1 | 0.44 |
| SEA-HPFH | 1 | 0.44 |
| 基因型 | 例数/例 | 检出率/% |
|---|---|---|
| 轻型 | ||
| CD17 | 88 | 39.12 |
| IVS-Ⅱ-654 | 55 | 24.45 |
| CD41-42 | 48 | 21.33 |
| CD43 | 8 | 3.56 |
| CD27-28 | 6 | 2.67 |
| βE | 6 | 2.67 |
| -28 | 5 | 2.22 |
| CD71-72 | 4 | 1.78 |
| 罕见型 | ||
| CD37 | 1 | 0.44 |
| -31 | 1 | 0.44 |
| CD59 | 1 | 0.44 |
| IVS-Ⅱ-143 | 1 | 0.44 |
| SEA-HPFH | 1 | 0.44 |
| 基因型 | 例数/例 | 检出率/% |
|---|---|---|
| -α3.7/αα复合IVS-Ⅱ-654 | 2 | 28.57 |
| -α3.7/αα复合CD41-42 | 2 | 28.57 |
| --SEA/ αα复合IVS-Ⅱ-654 | 1 | 14.29 |
| --SEA/αα复合CD41-42 | 1 | 14.29 |
| αααanti4.2复合IVS-Ⅱ-654 | 1 | 14.29 |
| 基因型 | 例数/例 | 检出率/% |
|---|---|---|
| -α3.7/αα复合IVS-Ⅱ-654 | 2 | 28.57 |
| -α3.7/αα复合CD41-42 | 2 | 28.57 |
| --SEA/ αα复合IVS-Ⅱ-654 | 1 | 14.29 |
| --SEA/αα复合CD41-42 | 1 | 14.29 |
| αααanti4.2复合IVS-Ⅱ-654 | 1 | 14.29 |
| 组别 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| α-地贫组 | 184 | 68.90 (63.13,80.08) | 21.30 (19.60,25.38) |
| β-地贫组 | 197 | 63.20 (59.40,67.25)* | 19.50 (18.60,20.80)* |
| α-地贫复合β-地贫组 | 5 | 68.90 (66.50,80.70) | 21.70 (19.75,26.40) |
| 地贫基因阴性组 | 736 | 90.00 (80.63,96.88)*#∆ | 30.00 (25.63,32.80)*#∆ |
| H值 | 511.186 | 446.978 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| α-地贫组 | 184 | 68.90 (63.13,80.08) | 21.30 (19.60,25.38) |
| β-地贫组 | 197 | 63.20 (59.40,67.25)* | 19.50 (18.60,20.80)* |
| α-地贫复合β-地贫组 | 5 | 68.90 (66.50,80.70) | 21.70 (19.75,26.40) |
| 地贫基因阴性组 | 736 | 90.00 (80.63,96.88)*#∆ | 30.00 (25.63,32.80)*#∆ |
| H值 | 511.186 | 446.978 | |
| P值 | <0.001 | <0.001 |
| 基因型 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| --SEA/αα | 118 | 65.55 (61.35,69.00) | 20.30 (19.08,21.53) |
| -α3.7/αα | 46 | 82.20 (79.45,84.65)**# | 26.30 (25.28,27.35)**## |
| -α4.2/αα | 9 | 80.40 (68.90,84.20)** | 26.20 (22.15,27.85)** |
| αCS/αα | 7 | 80.80 (78.10,83.20)* | 25.70 (25.20,27.00)* |
| --SEA/-α3.7 | 4 | 65.05 (60.70,80.20) | 19.35 (18.23,21.83) |
| H值 | 88.902 | 85.862 | |
| P值 | <0.001 | <0.001 |
| 基因型 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| --SEA/αα | 118 | 65.55 (61.35,69.00) | 20.30 (19.08,21.53) |
| -α3.7/αα | 46 | 82.20 (79.45,84.65)**# | 26.30 (25.28,27.35)**## |
| -α4.2/αα | 9 | 80.40 (68.90,84.20)** | 26.20 (22.15,27.85)** |
| αCS/αα | 7 | 80.80 (78.10,83.20)* | 25.70 (25.20,27.00)* |
| --SEA/-α3.7 | 4 | 65.05 (60.70,80.20) | 19.35 (18.23,21.83) |
| H值 | 88.902 | 85.862 | |
| P值 | <0.001 | <0.001 |
| 基因型 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| CD17 | 75 | 63.50 (60.20,66.50) | 19.50 (18.80,20.50) |
| IVS-Ⅱ-654 | 52 | 63.65 (59.43,67.65) | 19.55 (18.80,20.80) |
| CD41-42 | 39 | 62.40 (59.30,66.40) | 19.20 (18.50,20.60) |
| CD43 | 8 | 59.80 (57.30,63.65)# | 18.75 (17.98,19.88) |
| CD27-28 | 6 | 61.20 (57.48,73.13) | 18.85 (15.50,23.35) |
| βE | 6 | 77.70 (76.10,82.60)*##∆▲ | 25.95 (25.40,26.78)*##∆▲ |
| 基因型 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| CD17 | 75 | 63.50 (60.20,66.50) | 19.50 (18.80,20.50) |
| IVS-Ⅱ-654 | 52 | 63.65 (59.43,67.65) | 19.55 (18.80,20.80) |
| CD41-42 | 39 | 62.40 (59.30,66.40) | 19.20 (18.50,20.60) |
| CD43 | 8 | 59.80 (57.30,63.65)# | 18.75 (17.98,19.88) |
| CD27-28 | 6 | 61.20 (57.48,73.13) | 18.85 (15.50,23.35) |
| βE | 6 | 77.70 (76.10,82.60)*##∆▲ | 25.95 (25.40,26.78)*##∆▲ |
| 基因型 项目 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| 地贫基因阴性组 | |||
| 男性 | 248 | 92.40 (88.35,99.10) | 30.60 (29.30,34.30) |
| 女性 | 488 | 88.10 (77.93,94.80)* | 28.90 (24.00,31.80)* |
| 地贫基因阳性组 | |||
| 男性 | 115 | 63.00 (58.20,68.90)*# | 19.40 (18.30,20.60)*# |
| 女性 | 271 | 66.80 (61.80,73.00)*#∆ | 20.60 (19.20,22.80)*#∆ |
| H值 | 17.847 | 17.740 | |
| P值 | 0.003 | 0.003 |
| 基因型 项目 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| 地贫基因阴性组 | |||
| 男性 | 248 | 92.40 (88.35,99.10) | 30.60 (29.30,34.30) |
| 女性 | 488 | 88.10 (77.93,94.80)* | 28.90 (24.00,31.80)* |
| 地贫基因阳性组 | |||
| 男性 | 115 | 63.00 (58.20,68.90)*# | 19.40 (18.30,20.60)*# |
| 女性 | 271 | 66.80 (61.80,73.00)*#∆ | 20.60 (19.20,22.80)*#∆ |
| H值 | 17.847 | 17.740 | |
| P值 | 0.003 | 0.003 |
| 项目 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| 地贫基因阴性组 | |||
| 0~18岁 | 223 | 99.80 (95.80,103.30) | 34.40 (32.80,35.50) |
| 19~50岁 | 481 | 87.90 (78.85,91.50)* | 28.90 (24.50,30.50)* |
| >50岁 | 32 | 79.20 (68.88,95.68)*# | 23.55 (18.63,30.93)*# |
| 地贫基因阳性组 | |||
| 0~18岁 | 127 | 59.70 (57.80,63.10)*#∆ | 18.80 (18.10,19.80)*#∆ |
| 19~50岁 | 224 | 68.20 (64.30,77.03)*#∆▲ | 21.25 (19.93,24.70)*#∆▲ |
| >50岁 | 35 | 67.30 (62.40,70.20)*#∆▲ | 20.10 (18.90,21.60)*#∆▲□ |
| H值 | 41.805 | 69.502 | |
| P值 | <0.001 | <0.001 |
| 项目 | 例数 | MCV/fL | MCH/pg |
|---|---|---|---|
| 地贫基因阴性组 | |||
| 0~18岁 | 223 | 99.80 (95.80,103.30) | 34.40 (32.80,35.50) |
| 19~50岁 | 481 | 87.90 (78.85,91.50)* | 28.90 (24.50,30.50)* |
| >50岁 | 32 | 79.20 (68.88,95.68)*# | 23.55 (18.63,30.93)*# |
| 地贫基因阳性组 | |||
| 0~18岁 | 127 | 59.70 (57.80,63.10)*#∆ | 18.80 (18.10,19.80)*#∆ |
| 19~50岁 | 224 | 68.20 (64.30,77.03)*#∆▲ | 21.25 (19.93,24.70)*#∆▲ |
| >50岁 | 35 | 67.30 (62.40,70.20)*#∆▲ | 20.10 (18.90,21.60)*#∆▲□ |
| H值 | 41.805 | 69.502 | |
| P值 | <0.001 | <0.001 |
| [1] | DONG B Q, CHEN B Y, LIANG Q Y, et al. Study on the characteristics of major birth defects in 1.69 million cases of fetus in Guangxi Zhuang Autonomous Region[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2019, 40(12):1554-1559. |
| [2] | YAO X Y, YU J, CHEN S P, et al. Prevalence and genetic analysis of α-thalassemia and β-thalassemia in Chongqing area of China[J]. Gene, 2013, 532(1):120-124. |
| [3] |
ANGELUCCI E, MATTHES-MARTIN S, BARONCIANI D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease:indications and management recommendations from an international expert panel[J]. Haematologica, 2014, 99(5):811-820.
DOI URL |
| [4] |
FERRARI G, CAVAZZANA M, MAVILIO F. Gene therapy approaches to hemoglobinopathies[J]. Hematol Oncol Clin North Am, 2017, 31(5):835-852.
DOI URL |
| [5] | 中国医疗保健国际交流促进会基层检验技术标准化分会. 基层医学实验室血液分析系统应用专家共识[J]. 中华预防医学杂志, 2021, 55(12):1387-1398. |
| [6] | OLD J, HARTEVELD C L, TRAEGER-SYNODINOS J, et al. Prevention of thalassaemias and other haemoglobin disorders:volume 2:laboratory protocols[M]. 2nd ed. Nicosia(Cuprus): Thalassaemia International Federation, 2012. |
| [7] | 徐湘民. 地中海贫血预防控制操作指南[M]. 北京: 人民军医出版社, 2011. |
| [8] | 中华医学会围产医学分会, 中华医学会妇产科学分会产科学组. 地中海贫血妊娠期管理专家共识[J]. 中华围产医学杂志, 2020, 23(9):577-584. |
| [9] |
ZENG Y T, HUANG S Z. Disorders of haemoglobin in China[J]. J Med Genet, 1987, 24(10):578-583.
PMID |
| [10] | 王霞, 江虹, 贾劲, 等. 四川地区人群地中海贫血的筛查及基因分析[J]. 生物医学工程学杂志, 2011, 28(1):135-137. |
| [11] | 王紫玉. 成都地区0—18岁地中海贫血患儿的基因突变类型及频率分析[D]. 泸州: 西南医科大学, 2022. |
| [12] |
KATTAMIS A, KWIATKOWSKI J L, AYDINOK Y. Thalassaemia[J]. Lancet, 2022, 399(10343):2310-2324.
DOI PMID |
| [13] |
YIN X L, WU Z K, HE Y Y, et al. Treatment and complications of thalassemia major in Guangxi,southern China[J]. Pediatr Blood Cancer, 2011, 57(7):1174-1178.
DOI URL |
| [14] |
YIN A, LI B, LUO M, et al. The prevalence and molecular spectrum of α- and β-globin gene mutations in 14 332 families of Guangdong Province,China[J]. PLoS One, 2014, 9(2):e89855.
DOI URL |
| [15] |
ZHANG J, HE J, MAO X, et al. Haematological and electrophoretic characterisation of β-thalassaemia in Yunnan province of southwestern China[J]. BMJ Open, 2017, 7(1):e013367.
DOI URL |
| [16] |
YU X, YANG L Y, YANG H T, et al. Molecular epidemiological investigation of thalassemia in the Chengdu Region,Sichuan Province,southwest China[J]. Hemoglobin, 2015, 39(6):393-397.
DOI URL |
| [17] | 北京天使妈妈慈善基因会, 中华思源工程扶贫基因会,北京师范大学中国公益研究院. 中国地中海贫血蓝皮书[M]. 北京: 中国社会出版社, 2016. |
| [18] | SHANG X, PENG Z, YE Y, et al. Rapid targeted next-generation sequencing platform for molecular screening and clinical genotyping in subjects with hemoglobinopathies[J]. EBioMedicine, 2017,23:150-159. |
| [19] | 谢美娟. 云南省两个地区地中海贫血流行病学调查及新发现地中海贫血突变类型的研究[D]. 昆明: 昆明理工大学, 2021. |
| [20] | 尚陈宇. 广州地区地中海贫血基因型分布最新调查及鉴别筛查方程的建立[D]. 广州: 广州中医药大学, 2020. |
| [21] | 王林铄. 福建地区地中海贫血基因突变谱和产前基因诊断的特点[D]. 福州: 福建医科大学, 2015. |
| [22] | 唐腊梅. 湖南地区3 234例地中海贫血样本基因型及MCV、MCH分析[D]. 长沙: 中南大学, 2021. |
| [23] | 陈冬梅. 5 488例常见地中海贫血基因分析及罕见香港型地中海贫血基因型鉴定[D]. 泸州: 西南医科大学, 2020. |
| [24] | 伍莎莎, 蒋凡, 项贵明, 等. 重庆地区2 850例地中海贫血患者基因分析[J]. 重庆医学, 2019, 48(3):456-459. |
| [25] | 梁玉全, 周远青, 刘巧媛, 等. 性别、年龄及基因缺陷类型对β地中海贫血患者血液学指标的影响[J]. 广东医学, 2015,16:2546-2548. |
| [26] | 周晓萍, 刘腾, 庞雪利, 等. 地中海贫血基因检测结果及血液学表型分析[J]. 中国实验血液学杂志, 2022, 30(5):1527-1531. |
| [1] | WANG Bing, YANG Yuwei, LIU Junmei, LI Yanqiu, PENG Bi. Application of reticulocyte hemoglobin content in diagnosing thalassemia in children [J]. Laboratory Medicine, 2026, 41(1): 47-51. |
| [2] | DAI Jingwen, YANG Shuo, WANG Chong, SUN Lin, GU Meixiu, XIAN Jingrong, PAN Baishen, WANG Beili, ZHANG Chunyan, GUO Wei. Role of preoperative mean corpuscular hemoglobin concentration for predicting postoperative recurrence in intrahepatic cholangiocarcinoma patients [J]. Laboratory Medicine, 2025, 40(4): 344-349. |
| [3] | LING Xiaoting, PAN Liqiu, HUANG Yunhua, WEI Yuanyuan, DENG Xiaohui, YE Lihua, LIN Faquan, HUANG Yifang. Establishment of machine learning discriminatory formulas for thalassemia and iron deficiency anemia based on red blood cell morphology and parameters [J]. Laboratory Medicine, 2025, 40(4): 365-371. |
| [4] | ZHAO Yanan, XIAO Weili, CAO Qixin, YAN Yan, CUI Xiuge, ZHAO Jianping. Relation of drug resistance,serotypes and genotypes of Group B Streptococcus in perinatal pregnant females and pregnancy outcomes [J]. Laboratory Medicine, 2024, 39(4): 382-386. |
| [5] | LI Keke, XIAO Yang. Research progress of coagulation factor Ⅴ and its association with hemorrhage and thrombosis [J]. Laboratory Medicine, 2022, 37(4): 396-399. |
| [6] | LI Renqiang, LUO Junfeng, CHEN Yundi. Establishment and evaluation of α-thalassemia and β-thalassemia mutation determinations using hetero-tail dual-labeled fluorescent probe hydridization [J]. Laboratory Medicine, 2022, 37(10): 955-962. |
| [7] | WANG Jingjing, WU Linqing, CHEN Rushou, WANG Yufeng. Drug resistance genotype,transposon structure and MLSA of vancomycin-resistant Enterococcus [J]. Laboratory Medicine, 2021, 36(9): 891-895. |
| [8] | FANG Zhongjun, JI Weiqing, ZHANG Jingxian, WU Jintao, WU Weihua, JIANG Ying, HAN Zhenge, HE Dongyi, BIAN Yanqin, SHEN Yu, XIAO Lianbo, XIE Donghao, SUN Yang. HLA-B*5801 gene carrying rate and laboratory testing indicators in patients with gouty arthritis [J]. Laboratory Medicine, 2021, 36(9): 896-900. |
| [9] | JIAO Ruibao, TANG Jibin, ZHOU Jiali, ZHU Juanjuan, CHEN Jizhong. Genotype polymorphism distribution of GPⅠa G873A and C807T in cardio-cerebrovascular disease and diabetes mellitus [J]. Laboratory Medicine, 2021, 36(6): 581-585. |
| [10] | GU Yuwei, WANG Chengyun, GU Ping, PAN Qiuhui, WANG Jing, CHEN Guangjie. Weak expression of antigen caused by the variation in the regulatory region of ABO allele and cause analysis [J]. Laboratory Medicine, 2021, 36(6): 637-641. |
| [11] | ZHUANG Qianmei, LIU Xiaolong, HUANG Hailong, WANG Yuanbai, ZHUANG Jianlong, XU Liangpu, HONG Guolin. Comparison of application of 4 screening models for thalassemia [J]. Laboratory Medicine, 2021, 36(2): 173-176. |
| [12] | SANG Guoxin, YI Wei, YANG Biqing, GUO Weixia, HUANG Kai, LIN Keqin, CHU Jiayou, YANG Zhaoqing. Analysis of cut-off values of MCV and MCH for screening thalassemia in adults in Dehong,Yunnan [J]. Laboratory Medicine, 2021, 36(12): 1206-1209. |
| [13] | GUO Ping, ZHUANG Lihua, CHEN Liting, WANG Jianbiao, WU Jianfeng. Roles of MCV,RDW and SAA in the progression of chronic hepatitis B [J]. Laboratory Medicine, 2020, 35(11): 1153-1157. |
| [14] | BI Xiaojie, HUANG Daochao, JIN Xianfu, JIANG Junyu, SU Zhengxian, CHEN Chaochao, SHEN Bo. Phenotype and genotype analysis of coagulation factor Ⅺ deficiency caused by a compound heterozygous mutation [J]. Laboratory Medicine, 2020, 35(10): 1036-1039. |
| [15] | LI Yumin, ZHANG Shuilan, KAN Lijuan, ZHANG Bing, TANG Huamei, LI Rui, ZHANG Xiuming. Molecular characteristics and phenotypes of rare variation of thalassemia gene [J]. Laboratory Medicine, 2019, 34(7): 613-616. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||